07.01.2013 Views

Sorted By Test Name - Mayo Medical Laboratories

Sorted By Test Name - Mayo Medical Laboratories

Sorted By Test Name - Mayo Medical Laboratories

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

NPCKM<br />

83118<br />

NPCMS<br />

89015<br />

abnormal metabolism of low density lipoprotein in homozygous and heterozygous fibroblasts. J Biol<br />

Chem 1986;261:16769-16774 2. Pentchev PG, Kruth HS, Comley ME, et al: Type C Niemann-Pick<br />

disease: a parallel loss of regulatory responses in both the uptake and esterification of low density<br />

lipoprotein-derived cholesterol in cultured fibroblasts. J Biol Chem 1986;261:16775-16780 3. Patterson<br />

M: Niemann-Pick Disease type C. Available from:<br />

http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=npc Reviewed July 22, 2008 4. Enns<br />

GM, Steiner RD, Cowan TM: Lysosomal Disorders. In Pediatric Endocrinology and Inborn Errors of<br />

Metabolism. Edited by K Sarafoglou, GF Hoffmann, KS Roth, New York, McGraw-Hill <strong>Medical</strong><br />

Division, 2009, pp 740<br />

Niemann-Pick Type C Disease, Known Mutation<br />

Clinical Information: Niemann-Pick type C (NPC) is an inherited disorder of cholesterol transport<br />

that results in an accumulation of unesterified cholesterol and lipids in the lysosomal/endosomal system<br />

and in various tissues. Although NPC belongs to a group of lysosomal disorders including Niemann-Pick<br />

types A and B, these diseases are metabolically and genetically distinct. Niemann-Pick types A and B are<br />

caused by mutations in the SMPD1 gene, which encodes the enzyme sphingomyelinase, whereas NPC is<br />

caused by mutations in the NPC1 or NPC2 genes. The incidence of NPC is approximately 1:120,000 to<br />

1:150,000 live births. Age of onset is variable and ranges from the perinatal period to adulthood. Clinical<br />

presentation is also highly variable. Infants may present with or without liver disease<br />

(hepatosplenomegaly) and respiratory failure. Those without liver failure and pulmonary disease may<br />

present with hypotonia and developmental delay. Most individuals are diagnosed during childhood with<br />

symptoms including ataxia, vertical supranuclear gaze palsy, dystonia, progressive speech deterioration,<br />

and seizures resulting in death by the second or third decade of life. Adult onset NPC is associated with a<br />

slower progression and is characterized by neurologic and psychiatric problems. NPC is inherited in an<br />

autosomal recessive manner, in which affected individuals carry 2 mutations in either the NPC1 or NPC2<br />

gene. Most mutations are family specific, although there are 2 mutations in the NPC1 gene which are<br />

more common than others. The G992W mutation is common in the French Acadian population of Nova<br />

Scotia. The I1061T mutation is the most common mutation worldwide, and is seen in patients of Hispanic<br />

and Western European (United Kingdom and France) descent. Full gene sequencing and analysis for large<br />

deletions and duplications of the NPC1 and NPC2 genes detect less common disease-causing mutations.<br />

The recommended first-tier test to screen for NPC is a biochemical test measuring cholesterol<br />

esterification coupled with filipin staining on a fibroblast specimen, NIEM/9313 Niemann-Pick Type C<br />

Detection, Fibroblasts. Molecular testing provides confirmation of a biochemical diagnosis or a basis for<br />

carrier testing of family members. Individuals with abnormal biochemical results are more likely to have<br />

2 identifiable mutations by molecular testing.<br />

Useful For: Carrier testing of individuals for Niemann-Pick disease type C (NPC) when familial<br />

mutations have been previously identified Diagnostic confirmation of NPC when familial mutations have<br />

been previously identified Prenatal testing when 2 familial mutations have been previously identified in<br />

an affected family member<br />

Interpretation: An interpretative report will be provided.<br />

Reference Values:<br />

An interpretive report will be provided.<br />

Clinical References: 1. NP-C Guidelines Working Group, Wraith JE, Baumgartner MR, et al:<br />

Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol Genet Metab<br />

2009 Sep-Oct;98(1-2):152-65 2. Park WD, O'Brien JF, Lundquist PA, et al: Identification of 58 novel<br />

mutations in Niemann-Pick disease type C: correlation with biochemical phenotype and importance of<br />

PTC1-like domains in NPC1. Hum Mutat 2003 Oct;22(4):313-325 3. Vanier MT: Niemann-Pick disease<br />

type C. Orphanet J Rare Dis. 2010 Jun 3;5:16<br />

Niemann-Pick Type C, Full Gene Analysis<br />

Clinical Information: Niemann-Pick type C (NPC) is an inherited disorder of cholesterol transport<br />

Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or <strong>Mayo</strong><strong>Medical</strong><strong>Laboratories</strong>.com Page 1312

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!